AB Science S.A Total Assets
AB Science S.A total assets. Based on the latest financial reports, AB Science S.A (AB) holds total assets worth €24.52 Million EUR (≈ $28.67 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AB company net worth for the company's overall valuation and market capitalisation.
Total Assets of AB Science S.A (2009–2025)
Total assets of AB Science S.A from 2009 to 2025. This chart illustrates how AB Science S.A's total assets have evolved over time, based on quarterly financial data. See AB Science S.A stock price for real-time trading data and today's change.
AB Science S.A - Asset Composition Analysis
AB Science S.A Total Assets Breakdown (December 2025)
AB Science S.A total assets breakdown as of December 2025. AB Science S.A's total assets of €24.52 Million consist of 57.9% current assets and 42.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 41.5% |
| Accounts Receivable | €3.49 Million | 14.2% |
| Inventory | €151.00K | 0.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.57 Million | 6.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how AB Science S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore AB Science S.A current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AB Science S.A's current assets represent 57.9% of total assets in 2025, a decrease from 93.2% in 2009.
- Cash Position: Cash and equivalents constituted 41.5% of total assets in 2025, up from 12.7% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 5.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 14.2% of total assets.
AB Science S.A Competitors by Total Assets
Key competitors of AB Science S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
AB Science S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.96 | 0.71 | 1.17 |
| Quick Ratio | 0.95 | 0.70 | 1.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-614.00K | €-5.91 Million | €3.74 Million |
AB Science S.A - Advanced Valuation Insights
This section examines the relationship between AB Science S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.00 |
| Latest Market Cap to Assets Ratio | 2.49 |
| Asset Growth Rate (YoY) | 5.8% |
| Total Assets | €24.52 Million |
| Market Capitalization | $61.05 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values AB Science S.A's assets at a significant premium (2.49x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: AB Science S.A's assets grew by 5.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for AB Science S.A (2009–2025)
The table below shows the annual total assets of AB Science S.A from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €24.52 Million ≈ $28.67 Million |
+5.83% |
| 2024-12-31 | €23.18 Million ≈ $27.09 Million |
-9.11% |
| 2023-12-31 | €25.50 Million ≈ $29.81 Million |
+6.95% |
| 2022-12-31 | €23.84 Million ≈ $27.87 Million |
+12.08% |
| 2021-12-31 | €21.27 Million ≈ $24.87 Million |
-28.35% |
| 2020-12-31 | €29.69 Million ≈ $34.71 Million |
+67.35% |
| 2019-12-31 | €17.74 Million ≈ $20.74 Million |
-21.12% |
| 2018-12-31 | €22.49 Million ≈ $26.29 Million |
-55.55% |
| 2017-12-31 | €50.60 Million ≈ $59.16 Million |
+33.12% |
| 2016-12-31 | €38.01 Million ≈ $44.44 Million |
+16.67% |
| 2015-12-31 | €32.58 Million ≈ $38.09 Million |
+4.16% |
| 2014-12-31 | €31.28 Million ≈ $36.56 Million |
-28.32% |
| 2013-12-31 | €43.63 Million ≈ $51.01 Million |
+45.53% |
| 2012-12-31 | €29.98 Million ≈ $35.05 Million |
+1.76% |
| 2011-12-31 | €29.46 Million ≈ $34.44 Million |
+0.22% |
| 2010-12-31 | €29.40 Million ≈ $34.37 Million |
+108.70% |
| 2009-12-31 | €14.09 Million ≈ $16.47 Million |
-- |
About AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyo… Read more